These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 3358891

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS, Tucker GT, Woods HF.
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [Abstract] [Full Text] [Related]

  • 4. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF, Boutagy J, Shenfield GM.
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [Abstract] [Full Text] [Related]

  • 5. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL.
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
    Kallio J, Huupponen R, Pyykkö K.
    Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
    Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL.
    J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
    [Abstract] [Full Text] [Related]

  • 20. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
    Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR.
    Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.